|
|
||||||||




* Department of Antibacterials, Immunology, and Cancer, Pfizer Global Research and Development, Groton, CT 06340;
Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada; and
Departments of Neurology and Microbiology and Molecular Genetics, University of California, Irvine, CA 92697
| Abstract |
|---|
|
|
|---|
1,6GlcNAc-branched complex-type (N-acetylglucosaminyltransferase V (Mgat5)) N-glycans on TCR are bound to galectins, an interaction that reduces TCR signaling by opposing agonist-induced TCR clustering at the immune synapse. Mgat5/ mice display late-onset spontaneous autoimmune disease and enhanced resistance to tumor progression and metastasis. In this study we examined the role of
1,6GlcNAc N-glycan expression in Th1/Th2 cytokine production and differentiation.
1,6GlcNAc N-glycan expression is enhanced by TCR stimulation independent of cell division and declines at the end of the stimulation cycle. Anti-CD3-activated splenocytes and naive T cells from Mgat5/ mice produce more IFN-
and less IL-4 compared with wild-type cells, the latter resulting in the loss of IL-4-dependent down-regulation of IL-4R
. Swainsonine, an inhibitor of Golgi
-mannosidase II, blocked
1,6GlcNAc N-glycan expression and caused a similar increase in IFN-
production by T cells from humans and mice, but no additional enhancement in Mgat5/ T cells. Mgat5 deficiency did not alter IFN-
/IL-4 production by polarized Th1 cells, but caused an
10-fold increase in IFN-
production by polarized Th2 cells. These data indicate that negative regulation of TCR signaling by
1,6GlcNAc N-glycans promotes development of Th2 over Th1 responses, enhances polarization of Th2 cells, and suggests a mechanism for the increased autoimmune disease susceptibility observed in Mgat5/ mice. | Introduction |
|---|
|
|
|---|
The expression of the branching
1,6-N-acetylglucosaminyltransferase V (Mgat5)3 N-linked glycans increases after T cell activation (7). Mgat5 is a medial Golgi enzyme that transfers GlcNAc from UDP-GlcNAc to the OH on carbon 6 of the
1,6-linked mannose of N-glycans present on newly synthesized glycoproteins. Glycoproteins are then transported through the trans-Golgi where the N-glycans are extended with N-acetyl-lactosamine and poly-N-acetyl-lactosamine and capped with sialic acid, fucose, and sulfate. Mgat5 branched N-glycans are the preferred intermediates for extension with poly-N-acetyl-lactosamine and serve as ligands for the galectin family of N-acetyl-lactosamine-binding lectins (8, 9). The TCR subunits are N-glycosylated, a fraction of which are modified by Mgat5 and poly-N-acetyl-lactosamine and bind to galectin-3 (7, 10). The nonlectin N-terminal domain of galectin-3 mediates rapid conversion into pentamers in the presence of multivalent ligands, thereby cross-linking glycoproteins in proportion to ligand concentrations (11). Galectin cross-linking of Mgat5-modified cell surface glycoproteins forms a dynamic lattice that opposes agonist-dependent TCR clustering (7).
Mgat5/ embryos develop normally, but mutant mice display abnormal responses to extrinsic stimuli (7, 12), including T cell hypersensitivity in vitro and in vivo. Agonist-induced TCR clustering was enhanced in Mgat5/ T cells, which lowered the threshold for TCR-dependent tyrosine phosphorylation, actin microfilament reorganization, Ca2+ mobilization, and T cell proliferation. In vivo, Mgat5/ mice display enhanced delayed-type hypersensitivity, increased susceptibility to experimental autoimmune encephalomyelitis, an
30% incidence of spontaneous autoimmune kidney glomerulonephritis between 12 and 18 mo of age (7), and delayed tumor progression in polyomavirus middle T transgenic mice (12); the latter may be due in part to enhanced antitumor immune activity. Susceptibility to autoimmune disease and antitumor immunity are strongly influenced by the relative differentiation of naive CD4+ T cells into either proinflammatory Th1 cells that secrete IFN-
and TNF-
or anti-inflammatory Th2 cells that secrete IL-4, IL-5, IL-10, and IL-13 (13, 14). Enhancement of TCR signaling by increasing Ag dose or affinity promotes Th1 and inhibits Th2 differentiation (15, 16, 17, 18). This suggests that the lowered T cell activation thresholds produced by Mgat5 glycan deficiency may promote autoimmunity and antitumor immunity by directly increasing Ag-induced Th1 differentiation. To explore this possibility, we have examined the role of Mgat5 modified N-glycans in Th1/Th2 cell development. We demonstrate that expression of
1,6GlcNAc-branched N-glycans selectively inhibits Th1 cell differentiation and enhances the polarization of Th2 cells.
| Materials and Methods |
|---|
|
|
|---|
Mgat5/ mice on the 129 background were described previously (12). DO11.10 TCR transgenic mice in BALB/c background were purchased from The Jackson Laboratory (Bar Harbor, ME). Murine CD4 T cells were isolated from spleens using the DETACHaBEAD Mouse CD4 Isolation Kit (Dynal Biotech, Great Neck, NY) according to the manufacturers protocol. CD3+ T cells were isolated using a negative selection column (R&D Systems, Minneapolis, MN). To generate murine Th1 and Th2 cells, naive T cells were isolated from CD4 T cells using the CD62L MACS positive selection system (Miltenyi Biotec, Auburn, CA) and stimulated with plate-bound anti-CD3 (10 µg/ml), soluble anti-CD28 (1 µg/ml), IL-12, and anti-IL4 for Th1 cells or with anti-CD3 (10 µg/ml), anti-CD28 (1 µg/ml), IL-4, and anti-IFN-
for Th2 cells. The cytokine concentrations and Abs used were described previously (19). For restimulation, cells were washed and stimulated with 1 µg/ml anti-CD3. For plant lectin leukoagglutinin (L-PHA) staining of in vitro differentiated Th1 and Th2 cells, splenocytes from DO11.10/Rag1 knockout mice were stimulated with 300 ng/ml OVA peptide and differentiating cytokines as described above. Human naive T cells were isolated from peripheral blood from normal volunteers using an Accuspin PBMC isolation kit (Sigma-Aldrich, St. Louis, MO), then using a CD4+CD45RO subset kit (R&D Systems).
Cytokine measurement using Bioplex
Cells are routinely stimulated at 1 million/ml, and supernatant was collected at various times after stimulation. In some cases, splenocytes were stimulated with 1 µg/ml anti-CD28 in combination with various concentrations of anti-CD3; in other cases, 1 µg/ml anti-CD3 was immobilized to the plate, then combined with 2 µg/ml anti-CD28 as stimulus. For restimulation, cells were washed and counted, and the same number of cells was plated per well. Cytokines were measured using Bioplex system (Bio-Rad, Hercules, CA); cytokine standard and reagent for measuring TNF-
were purchased from Upstate Biotechnology (Lake Placid, NY). For each experiment, triplicate samples were measured, and averages were taken for data analysis. In some cases, diluted samples were measured to fit the dynamic range of the standards, and cytokine concentrations in supernatant were calculated accordingly.
L-PHA and CFSE staining
Murine splenocytes or human T cells were stimulated as indicated in the figure legends and in some instances were treated with various concentrations of swainsonine and stained with FITC-conjugated L-PHA (Vector Laboratories, Burlingame, CA) for 15 min on ice, washed, and analyzed using FACS. A titration of L-PHA-FITC from 0.2 ng/ml to 200 µg/ml was performed initially, and all subsequent staining was performed using 2 µg/ml L-PHA-FITC. For CFSE staining and proliferation, purified CD3+ T cells were incubated with 5 µM CFSE for 8 min at room temperature, washed, and stimulated with plate-bound anti-CD3 with or without anti-CD28. After 3 days of culture, the cells were washed, stained with L-PHA-PE and anti-CD4-PE-Cy5, and analyzed by FACS.
Cytokine receptor FACS
Purified CD3+ T cells from Mgat5+/+ and Mgat5/ were stimulated with 1 µg/ml plate-bound wild-type anti-CD3 (clone 2C11) 48 h in the presence or the absence of rIL-4 (10 ng/ml), IL-12 (10 ng/ml), IFN-
(10 ng/ml), anti-IL-4 (10 µg/ml; clone 11B11), or anti-IFN-
(10 µg/ml; clone XMG1.2). All were obtained from eBioscience (San Diego, CA). Cells were then washed and stained with anti-IFN-
R
-FITC (clone 2E2; Santa Cruz Biotechnology, Santa Cruz, CA), anti-IL-4R
-PE (clone mIL4R-M1; BD Biosciences), and anti-CD4-PE-Cy5 (clone GK1.5; eBioscience).
Real-time PCR
Th1 and Th2 cells differentiated in vitro from purified CD4+L-selectin+ cells were washed, and RNA was extracted using an RNeasy kit (Qiagen, Valencia, CA). RNA was quantitated using a spectrophotometer, and the same amount of RNA from each sample was used to make cDNA and was used as a template for real-time PCR. Each experimental time point sample was used as a template for primer pairs on separate MicroAmp optical 96-well reaction plates using the GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, CA). To determine the expression ratios between cells induced to differentiate for various time points, all values were normalized to
-actin according to equation: (Ctbaseline Cttrmt)YFG (Ctbaseline Cttrmt)actin =
Ct, then the ratio between treatment and baseline was calculated as 2|
Ct|. The sign of the value for
Ct indicates either up or down-regulation. The primer sequences used were: for Mgat5, 5'-GGAAATGGCCTTGAAAACACA-3' and 5'-CAAGCACACCTGGGATCCA-3'; and for
-actin 5'-CCAGCAGATGTGGATCAGCA-3' and 5'-TTGCGGTGCACGATGG-3'. For IFN-
and IL-4 TaqMan analysis, the murine IFN-
and IL-4 analysis kit from Applied Biosystems was used.
| Results |
|---|
|
|
|---|
1,6GlcNAc-branched N-glycan after T cell activation
We have previously shown that T cell activation with anti-CD3 and anti-CD28 Abs significantly increases Mgat5 gene transcription and cell surface
1,6GlcNAc-branched N-glycans (7). The L-PHA binds specifically to mature Mgat5-modified N-glycans (20). Staining of Mgat5+/+, Mgat5+/, and Mgat5/ resting CD4+ T cells with L-PHA-FITC confirmed that Mgat5/ cells lack specific L-PHA staining (Fig. 1a). Mgat5+/ cells had approximately half the staining of wild-type cells, indicating that L-PHA staining is a sensitive and accurate measure of relative differences in Mgat5 N-glycan expression and is consistent with our previous finding that Mgat5 enzyme activity in tissues from heterozygous mice is
50% that in wild-type mice (12). This suggests that Mgat5 enzyme activity is rate-limiting for
1,6GlcNAc-branched products in T cells. Wild-type T cells were labeled with CFSE to track Mgat5 N-glycan expression through each cell division. After stimulation with anti-CD3 with or without anti-CD28 Abs, Mgat5 N-glycan expression increased in all cell divisions from 0 to 4, peaking within zero to two cell divisions, then declining modestly with subsequent divisions (Fig. 1, bg). Interestingly, undivided cells in both the CD3- and CD3/CD28-stimulated cultures significantly increased L-PHA staining, indicating that the induction of Mgat5 activity occurs early and does not require cell division. The intensity of L-PHA staining was dependent on the initial stimulus, because increasing the anti-CD3 concentration or adding CD28 both maximized L-PHA staining to
300% above that in nonstimulated cells (Fig. 1g). Because the Mgat5 promoter has Ets and AP-1 binding sites and is responsive to the Ras signaling pathway (21, 22), these data suggest that Mgat5 expression is directly induced by TCR and CD28 signaling. Furthermore, the data indicate that
1,6GlcNAc-branched N-glycan expression is tightly regulated during T cell activation and subsequent cell divisions.
|
Splenocytes from Mgat5/ and wild-type littermates were stimulated with soluble anti-CD3 with or without anti-CD28 for 3 days. Proliferation, measured by [3H]thymidine incorporation, increased in Mgat5/ spleen cells, compared with that in wild-type cultures (Fig. 2a), 4- to 5-fold with anti-CD3 and 2- to 3-fold in anti-CD3 and anti-CD28 cultures. Cytokine production and proliferation index peaked at
0.5 µg/ml anti-CD3 Abs for both mutant and wild-type cultures (Fig. 2b). Before normalizing for proliferation, Mgat5/ cultures produced significantly more IFN-
, IL-2, TNF-
, and IL-10 than wild-type cells. However, after normalizing cytokine production for proliferation, Mgat5/ cells produced
2-fold more IFN-
and
2-fold less IL-4 on a per cell basis in both anti-CD3- and anti-CD3/anti-CD28-stimulated cultures (Fig. 2c). Strikingly, anti-CD3-stimulated Mgat5/ cells produced markedly more IFN-
per cell then anti-CD3- and anti-CD28-costimulated wild-type cells. This coupled with the fact that the addition of anti-CD28 to Mgat5/ cells did not significantly increase the production of IFN-
per cell over that of anti-CD3 alone indicates that Mgat5 glycan deficiency sensitizes cells for IFN-
production much more effectively then CD28 costimulation. Moreover, CD28 costimulation was unable to compensate for Mgat5 glycan deficiency in per cell production of IL-4, because anti-CD3- and anti-CD28-costimulated Mgat5/ cells secreted significantly less IL-4 then Mgat5+/+ cells stimulated with only anti-CD3. An increase in per cell production of IL-10 was also observed in Mgat5/ anti-CD3- and anti-CD28-costimulated cultures (Fig. 2c), but, as demonstrated in Fig. 4, this was due to a non-T cell population (see below).
|
|
production in splenocyte cultures
The alkaloid swainsonine is a competitive inhibitor of Golgi
-mannosidase II, which blocks the N-glycan biosynthetic pathway before
1,6GlcNAc branching and results in the production of hybrid-type glycans. Swainsonine is nontoxic in cell culture and has been shown to enhance T cell proliferation and IL-2 production (23). Stimulation of T cells in cultured splenocytes displayed a peak of IFN-
and IL-4 production on day 3, whereas IL-10 increased until day 5 (Fig. 3a). Treatment with swainsonine significantly increased IFN-
and IL-10 production in cultures stimulated with anti-CD3 Abs alone or combined with anti-CD28 Abs. IFN-
and IL-10 production reached a maximum with 0.5 µM swainsonine, whereas cytokine production was reduced by 1 µM swainsonine (data not shown). Under these conditions, no significant increase in cell number was seen (data not shown).
|
production over that with either stimulant alone (Fig. 3b). Thus, both swainsonine and the Mgat5 mutation enhanced IFN-
production from splenocytes through the same or similar pathways.
Mgat5 and IFN-
/IL-4 production by CD4+ cells
Because multiple cell types in spleen cell cultures can contribute to cytokine production, we evaluated the contribution by CD4+ Th cells alone. Mgat5 deficiency enhanced IFN-
and decreased IL-4 production in naive CD4+ T cells (CD4+CD62L+) on a per cell basis when stimulated with plate-bound anti-CD3 and anti-CD28 Abs (Fig. 4). Swainsonine treatment of purified naive CD4 T cells (CD4+CD62L+) also enhanced IFN-
production (data not shown). However, no difference between genotypes in IL-10 production per cell was observed in these cultures from days 13. On day 6, there was a small decrease in the amount of IL-10 secreted per cell in the Mgat5/ cultures. These data indicate that a non-T cell population contributed to the enhanced IL-10 production in swainsonine-treated and Mgat5/ spleen cell cultures.
To evaluate whether
1,6GlcNAc-branched N-glycans also influence Th1 and Th2 differentiation of human T cells, we examined the effect of swainsonine treatment on cytokine production by human naive T cells. Swainsonine inhibited cell surface L-PHA staining on both CD4+ and CD4 T cells purified from peripheral blood in a dose-dependent manner at concentrations of 0.10.5 µM (Fig. 5a), and no further inhibition was achieved at 1 µM (data not shown). Swainsonine inhibited the majority of L-PHA staining, yet a small population of L-PHA-positive cells persisted, suggesting a minor or alternate pathway to complex-type N-glycans that uses
-mannosidase IIX is functional in these cells (24). Naive T cells (CD4+CD45RO) were stimulated with anti-CD3 and anti-CD28. IL-2 reached peak level on day 2, whereas IFN-
and IL-10 reached their highest levels 3 days after stimulation (Fig. 5b). Swainsonine alone did not stimulate IFN-
and IL-10 production, but addition of swainsonine with either anti-CD3 Abs or anti-CD3 plus anti-CD28 Abs increased IFN-
production. IL-10 production was not enhanced by swainsonine treatment. The absolute amount of cytokine production varied among donors, yet swainsonine induced a consistent dose-dependent stimulation of IFN-
.
|
1,6GlcNAc-branched N-glycans in Th1 and Th2 cells
Enhancement of IFN-
and reduced IL-4 production in Mgat5/ T cells suggest differential roles of
1,6GlcNAc-branched N-glycans in Th1 and Th2 cells. We therefore examined the L-PHA staining pattern in Th1 and Th2 cells differentiated in vitro. Splenocytes from DO11.10/Rag1/ mice were stimulated with Ag under Th1 or Th2 conditions in vitro, and the expression of
1,6GlcNAc-branched N-glycans on CD4 T cells was examined with L-PHA staining. Naive T cells in the nonstimulated sample were mostly small cells (as shown by forward scatter; Fig. 6a) with low L-PHA staining. L-PHA staining in both Th1 and Th2 cells gradually increased during the early part of the time course and decreased somewhat at the end of the stimulation cycle relative to the peak level. Although no dramatic differences in overall mean fluorescence of L-PHA staining were seen between Th1 and Th2 cells, some differences in the L-PHA staining pattern were apparent. In Th1 cells, the L-PHA staining at each stage was roughly proportional to cell size, i.e., when cells got bigger after several days of stimulation, they acquired more L-PHA staining, whereas this was not the case for Th2 cells (Fig. 6a). To further examine the Mgat5 gene expression pattern in Th1 and Th2 cells, we performed real-time PCR analysis of Mgat5 message in purified Th cell populations. Similar to the results from L-PHA staining, on day 4 after TCR stimulation and Th1 Th2 differentiation, a small increase in Mgat5 expression was seen in Th1 compared with Th2 cells. In this system, Th cells did not express a large quantity of cytokines unless restimulated. To examine Mgat5 expression during active cytokine expression, we restimulated Th1 and Th2 cells with TCR-stimulating Ab and analyzed Mgat5 expression at 4 h postrestimulation, when T cells were actively secreting cytokines. A dramatic increase in Mgat5 expression level was seen in both Th1 and Th2 cells upon restimulation, which coincided with high levels of IFN-
and IL-4 expression in Th1 and Th2 cells, respectively (Fig. 6b). Interestingly, when restimulated, Th1 cells consistently displayed higher Mgat5 expression than Th2 cells.
|
Because greater affinity of TCR-ligand binding can favor the development of the Th1 response, the hypersensitivity of TCR in Mgat5/ T cells may initiate early events that mediate subsequent feedback regulation of CD4+ T cells. To examine CD4+ cell responsiveness, as reflected by changes in cell surface receptors, we measured IL-4, IFN-
, and IL-12 receptors during stimulation. Resting CD4+ T cells from Mgat5+/+ and Mgat5/ CD4+ T cells displayed similar levels of IL-4R
and IFN-
R
, whereas no IL-12R
2 was detected in either genotype (Fig. 7a and data not shown). After TCR stimulation, surface IL-4R
was down-regulated significantly in Mgat5+/+ cells, but decreased only minimally in Mgat5/ T cells (Fig. 7a). IFN-
R
levels did not change with stimulation and were unaffected by the Mgat5 mutation (Fig. 7a). Similarly, IL-12R
2 staining was negative in both cells at rest and was similarly increased at 5 days after anti-CD3 stimulation (data not shown). The addition of exogenous IL-4 eliminated surface IL-4R
in both Mgat5+/+ and Mgat5/ cells, indicating that IL-4 cytokine causes a dose-dependent feedback suppression of IL-4R
expression. Confirming this interpretation, anti-IL-4 Ab restored IL-4R
surface expression in Mgat5+/+ cells to the same level as in Mgat5/ cells (Fig. 7b). Anti-IFN-
Abs and exogenous IL-12 and IFN-
had no effect on receptor levels (Fig. 7). Therefore, IL-4R
down-regulation is secondary to increased production of endogenous IL-4, which is reduced in Mgat5-deficient T cell cultures. This confirms that Mgat5 glycans promote IL-4 secretion during T cell activation and demonstrates a functional alteration in Mgat5/ cells.
|
production by Th1 cells (Table I). However, IFN-
produced by Mgat5/ Th2 polarized cells was
10-fold higher than that produced by wild-type Th2 cells, although the absolute IFN-
level was
15 times lower than that of Th1 polarized cells (Table I). These data indicate that Mgat5 deficiency does not significantly alter IFN-
production by Th1 cells under polarizing conditions, but weakens the polarization of Th2 cells upon restimulation.
|
| Discussion |
|---|
|
|
|---|
1,6GlcNAc-branched N-glycans suppress the production of the major Th1 cytokine IFN-
and promote the expression of the Th2-inducing cytokine IL-4 in TCR-stimulated splenocytes and naive CD4+ T cells. The magnitude of this effect was highly significant, because Mgat5 glycan deficiency enhanced IFN-
/cell production more effectively then CD28 costimulation, and CD28 costimulation was unable to restore the reduced IL-4/cell production by Mgat5/ cells to that produced by noncostimulated wild-type splenocytes. The reduced IL-4 production by activated Mgat5/ T cells was associated with decreased ligand-induced IL-4R
down-regulation. In contrast,
1,6GlcNAc-branched N-glycans did not significantly alter IFN-
R
or IL-12R
2 expression. Analysis of TCR-stimulated Th1 and Th2 polarized cells demonstrated that
1,6GlcNAc-N-glycan deficiency enhanced IFN-
production by polarized Th2 cells
10-fold, but did not alter the cytokine profile of polarized Th1 cells. Taken together, these data indicate that Mgat5 glycans promote the differentiation and enhance the polarization of Th2 cells.
IFN-
and IL-12 promote Th1, whereas IL-4 enhances Th2 differentiation, respectively. IFN-
-mediated signaling via the STAT1 signaling pathway induces expression of the transcription factor t-bet, which, in turn, induces expression of IL-12R
2 and commits the cell to Th1 differentiation (25, 26). However, Th1/Th2 differentiation by naive CD4+ T cells is also strongly regulated by the potency of the initial TCR signal, because greater ligand affinity or dose promotes IFN-
production and Th1 differentiation over IL-4 secretion and Th2 lineage commitment (15, 16, 17, 18). Mgat5-modified N-glycans on TCR regulate TCR association with a multivalent galectin-glycoprotein lattice that restricts ligand-induced TCR recruitment to the immune synapse (7). The absence of Mgat5-modified N-glycans weakens the lattice, thereby enhancing agonist-induced TCR clustering, signaling, and proliferation. Taken together these data indicate that deficiency of
1,6GlcNAc-branched N-glycans promotes IFN-
production and Th1 differentiation by directly increasing the strength of primary TCR signals. Thus, differential regulation of Mgat5 N-glycan expression represents an Ag-independent mechanism to regulate naive CD4+ T cell proliferation and Th1/Th2 differentiation during a primary immune response.
Mgat5/ mice spontaneously develop late-onset kidney autoimmune disease and are more susceptible to experimental autoimmune encephalomyelitis, the animal model for multiple sclerosis (7). Although not consistent for all types of autoimmunity and experimental systems, IFN-
and Th1 responses predominantly promote, whereas IL-4 and Th2 responses largely inhibit, autoimmune disease (27). This suggests that the enhanced Th1 differentiation associated with Mgat5 deficiency promoted the loss of immune tolerance and autoimmunity observed in null mice. Although resting naive CD4+ T cells continuously engage self-peptide-MHC in the periphery, these interactions normally do not induce significant T cell proliferation or cytokine production, thereby maintaining self-tolerance (28). One likely explanation for this is the failure of self-peptide to activate APCs. Dendritic cells and macrophages express TLRs that recognize pathogen-associated molecular patterns, such as LPS, peptidoglycan, CpG DNA motifs, dsRNA, and bacterial flagellin (29). Recognition of these non-self microbial products by TLRs leads to up-regulation of MHC, CD28 costimulatory receptors B7-1/B7-2, and proinflammatory cytokines, significantly enhancing their ability to stimulate naive CD4+ T cells (29). The inability of self-peptide to trigger these events prevents naive CD4+ T cells from receiving the CD28 and cytokine costimulatory signals necessary for activation. Our previous and current work demonstrates that the increase in T cell proliferation and IFN-
production associated with Mgat5 deficiency is the same or greater than that produced by CD28 costimulation. Thus, in the appropriate in vivo setting, Mgat5/ naive CD4+ T cells may proliferate and secrete IFN-
in response to self-peptide-MHC despite presentation by unactivated or minimally activated APC. This may be sufficient to promote a Th1 response to self-peptide, the breakdown of self-tolerance, and autoimmunity.
1,6GlcNAc-branched N-glycans on TCR bind galectins, forming a multivalent lattice that inhibits TCR recruitment into the immune synapse (7), indicating an inhibitory role for
1,6GlcNAc-branched N-glycans in TCR signaling. After stimulation, Mgat5 glycan expression increases
300% within the first few cell divisions, then slowly declines. This suggests that Mgat5 acts early to limit further TCR stimulation. However, Mgat5 glycans also negatively regulate adhesion to fibronectin in cancer cells and fibroblasts, a function we have also observed in T cells (M. Demetriou and J. W. Dennis, unpublished observations). This raises the possibility that the increased expression of Mgat5 glycans early in the T cell proliferation cycle acts to reduce adhesion to fibronectin, thereby promoting departure from the site of Ag presentation in lymphoid tissues and recruitment to sites of infection/inflammation.
Mgat5 and
1,6GlcNAc-branched N-glycan expression in differentiating Th1 and Th2 cells were generally similar; however, when resting cells are restimulated via TCR, Th2 cells induce significantly less Mgat5 mRNA than Th1 cells. Th2 cells have reduced recruitment of TCR to the site of Ag presentation compared with Th1 cells, resulting in reduced TCR signaling events, such as calcium mobilization and tyrosine phosphorylation of Zap-70 and Fyn (30, 31, 32). Our finding that the strength of TCR stimulation regulates Mgat5 glycan expression (Fig. 1) is consistent with the reduced TCR clustering and signaling present in Th2 cells limiting Mgat5 mRNA up-regulation. Although the functional significance of this differential regulation is not clear, it may result in alterations in subsequent TCR activation and/or adhesion to fibronectin, both of which possibilities require further investigation.
IL-10 was increased in Mgat5/ splenocyte cultures, but not in purified T cells, suggesting that non-T cell populations contribute directly or indirectly to differential cytokine production. Macrophages are major producers of IL-10, and other sources of IFN-
include CD8 T cells and NK cells. A recent study showed that M150, a membrane protein on activated macrophages that promotes Th1 differentiation of naive T cells, is a uniquely glycosylated form of lysosomal-associated membrane protein-1 (33). Lysosomal-associated membrane protein-1 contains 20 Asn-linked glycosylation sites and is a major target for
1,6GlcNAc branching in cell lines with increased Mgat5 expression (34, 35, 36), suggesting that Mgat5 deficiency in macrophages may alter the ability of M150 to drive Th1 differentiation.
Mgat5 gene transcription is positively regulated by Ras-Raf-Ets (21, 22), a pathway commonly activated in cancer cells as well as activated T cells. Mgat5-modified glycans in human breast and colorectal carcinomas correlate with progression (34) and reduced patient survival time (37). Transfection of mouse mammary carcinoma cells with an Mgat5 expression vector enhances invasion and metastasis (38, 39). Conversely, tumor cell mutants selected for L-PHA resistance and found to be deficient in Mgat5 activity are also deficient for metastasis (40). In a transgenic model of mammary carcinoma, Mgat5 deficiency is associated with significantly reduced tumor growth and metastasis (12). These experiments suggest that Mgat5 regulates tumor cell autonomous phenotypes, but does not exclude the possibility that enhanced T cell activation in Mgat5/ mice also contributes to reduced tumor progression. For instance, the expression of a dominant negative form of TGF-
receptor in T cells is sufficient to induce immune rejection in wild-type tumors (41). The results presented in this study demonstrate enhanced Th1 cytokine production in Mgat5/ T cells, suggesting that enhanced Th1-mediated antitumor immunity may also play a role in tumor reduction in Mgat5/ mice.
Swainsonine is a potent low m.w. inhibitor of
-mannosidase II, an enzyme upstream of Mgat5 in the N-glycosylation pathway. Swainsonine has been shown to inhibit tumor growth and lung colonization in a number of animal models (42, 43, 44) and has demonstrated low toxicity as well as evidence of clinical efficacy in two phase I clinical trials (45). In addition to its direct effect on tumor cells, swainsonine enhances activation of Th cells (46), CTLs (47), NK and LAK cells (23, 48), as well as macrophages (49), all of which have potential for antitumor activity. In this study we show that swainsonine enhances IFN-
production, the key Th1 cytokine that stimulates CD8 cells and NK cells, the major effector cells involved in tumor eradication. Previous publications have shown that swainsonine has no effect on IFN-
production by murine splenocytes (39). However, these researchers used a much higher concentration of swainsonine. We found that the peak level of IFN-
stimulation occurs at
0.51 µM swainsonine, with IFN-
production leveling off when higher concentrations of swainsonine were used. Higher levels of swainsonine inhibit lysosomal
-mannosidases and cause high mannose storage, which may interfere with immune cell functions. Swainsonine might be considered a lead compound, and with a growing appreciation of its mechanism of action, an analog with improved specificity could be useful in cancer therapy.
| Footnotes |
|---|
1 This work was supported in part by grants from the National Institute of Allergy and Infectious Disease, National Institutes of Health (to M.D.), and the Canadian Institutes for Health Research (to J.W.D.). ![]()
2 Address correspondence and reprint requests to Dr. Baiyong Li, Department of Antibacterials, Immunology, and Cancer, Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340. E-mail address: baiyong_li{at}groton.pfizer.com ![]()
3 Abbreviations used in this paper: Mgat5, N-acetylglucosaminyltransferase V; L-PHA, plant lectin leukoagglutinin. ![]()
Received for publication March 23, 2004. Accepted for publication October 5, 2004.
| References |
|---|
|
|
|---|
(1,3)-fucosyltransferase VII and
(2,3)-sialyltransferase IV are up-regulated in activated CD4 T cells and maintained after their differentiation into Th1 and migration into inflammatory sites. J. Immunol. 163:3746.
-1,6-n-acetylglucosaminyltransferase, an enzyme essential for biosynthesis of P-selectin ligands. J. Immunol. 167:4476.
2,6-sialyltransferase induced early after lymphocyte activation. Int. Immunol. 11:731.
-transgenic model. J. Exp. Med. 182:1579.
-Mannosidase-II deficiency results in dyserythropoiesis and unveils an alternate pathway in oligosaccharide biosynthesis. Cell 90:157.[Medline]
16 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236:582.
16 branched Asn-linked oligosaccharides from metastatic tumour cells. Biochem. J. 259:569.[Medline]
16Man
16Man
1-branched asparagine-linked oligosaccharides in murine tissues and human breast carcinomas. Cancer Res. 49:945.
signaling in T cells. Nat. Med. 7:1118.[Medline]
2. J. Natl. Cancer Inst. 81:1028.This article has been cited by other articles:
![]() |
E. H. Duitman, Z. Orinska, E. Bulanova, R. Paus, and S. Bulfone-Paus How a Cytokine Is Chaperoned through the Secretory Pathway by Complexing with Its Own Receptor: Lessons from Interleukin-15 (IL-15)/IL-15 Receptor {alpha} Mol. Cell. Biol., August 1, 2008; 28(15): 4851 - 4861. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bouguermouh, V. Q. Van, J. Martel, P. Gautier, M. Rubio, and M. Sarfati CD47 Expression on T Cell Is a Self-Control Negative Regulator of Type 1 Immune Response J. Immunol., June 15, 2008; 180(12): 8073 - 8082. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Alavi and J. S. Axford Sweet and sour: the impact of sugars on disease Rheumatology, June 1, 2008; 47(6): 760 - 770. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, Y. Li, X. Wu, Q. Li, J. Yu, J. Gen, and X.-L. Zhang Knockdown of Mgat5 Inhibits Breast Cancer Cell Growth with Activation of CD4+ T Cells and Macrophages J. Immunol., March 1, 2008; 180(5): 3158 - 3165. [Abstract] [Full Text] [PDF] |
||||
![]() |
I-J. Chen, H.-L. Chen, and M. Demetriou Lateral Compartmentalization of T Cell Receptor Versus CD45 by Galectin-N-Glycan Binding and Microfilaments Coordinate Basal and Activation Signaling J. Biol. Chem., November 30, 2007; 282(48): 35361 - 35372. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-U. Lee, A. Grigorian, J. Pawling, I-J. Chen, G. Gao, T. Mozaffar, C. McKerlie, and M. Demetriou N-Glycan Processing Deficiency Promotes Spontaneous Inflammatory Demyelination and Neurodegeneration J. Biol. Chem., November 16, 2007; 282(46): 33725 - 33734. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Breuilh, F. Vanhoutte, J. Fontaine, C. M. W. van Stijn, I. Tillie-Leblond, M. Capron, C. Faveeuw, T. Jouault, I. van Die, P. Gosset, et al. Galectin-3 Modulates Immune and Inflammatory Responses during Helminthic Infection: Impact of Galectin-3 Deficiency on the Functions of Dendritic Cells Infect. Immun., November 1, 2007; 75(11): 5148 - 5157. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grigorian, S.-U. Lee, W. Tian, I.-J. Chen, G. Gao, R. Mendelsohn, J. W. Dennis, and M. Demetriou Control of T Cell-mediated Autoimmunity by Metabolite Flux to N-Glycan Biosynthesis J. Biol. Chem., July 6, 2007; 282(27): 20027 - 20035. [Abstract] [Full Text] [PDF] |
||||